Black Diamond Therapeutics, Inc. (BDTX) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US09203E1055

Price

1.86 USD

Market cap

107.07 m USD

P/E (2026)

–

P/S (2026)

–

Dividend yield

0.00 %

Net margin

–

Return on equity (ROE)

–

Return on assets (ROA)

–

Black Diamond Therapeutics, Inc. financials

Fiscal year	2025
Revenue	70.00 m USD
Operating income	12.52 m USD
EBIT	22.37 m USD
Net income	22.37 m USD
Diluted EPS – continuing operations	0.39 USD

Full history since 2017, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.